Siemens, Insightec partner on novel essential tremor treatment

Imaging giant Siemens Healthineers is teaming up with Israel’s Insightec to develop compatibility between the former’s MRI systems and the latter's noninvasive treatment for essential tremor in order to bring the novel treatment to more patients.

Insightec’s Exablate Neuro system won FDA approval just a month ago. It uses MR-guided ultrasound waves rather than incisions or implants to target and ablate tissue deep in the brain. The tie-up will involve Siemens’ Magnetom Aera and Skyra MRI systems and further the company’s push to “broaden and complement” its diagnostic imaging offerings with advanced therapies, the companies said in a statement.

Siemens expects to offer patient-specific treatment planning and continuous temperature monitoring during Exablate Neuro procedures, according to the statement. For Insightec, the collaboration will expand its reach in the essential tremor market: “Siemens has embraced our technology and together we will bring our therapy to significantly more patients and providers," said Insightec CEO Dr. Maurice Ferré, in the statement.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

Siemens rebranded its Healthcare unit as Siemens Healthineers in May this year, prompting speculation that it would spin off the separately managed business. As part of the rebrand, the company announced it would introduce new offerings, including managed services, consulting and digital services, as well as augmenting its therapeutic and molecular diagnostics capabilities.

Since the makeover, Siemens Healthineers has joined forces with Case Western Reserve University on MRI fingerprinting, that is, to make a diagnostic MRI uniquely identifiable for forensic use. While traditional MRI analysis is qualitative, Siemens wants to make it quantitative to improve the reproducibility of results across scanners and institutions. And later, the company delivered on its promise to grow in molecular diagnostics, picking up the German liquid biopsy startup Neo New Oncology.

- here's the statement

Related Articles:
FDA approves first standalone 3-D mammography system for Siemens
Siemens buys German liquid biopsy startup to enter molecular oncology Dx
Siemens, Case Western partner to develop MRI fingerprinting
Siemens rebrands healthcare biz as it seeks to expand, adding services and more molecular Dx
FDA approves noninvasive treatment for essential tremor
FDA nod for Siemens MRI software to reduce time needed for brain imaging